|Merrill, Jr., Alfred|
Submitted to: Patent Application
Publication Type: Patent Application
Publication Acceptance Date: 4/30/2003
Publication Date: 4/13/2004
Citation: Merrill, Jr., A.H., Wang, E.W., Liotta, D.C., Riley, R.T. 2004. Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination. U.S. Patent 6,720,184. Interpretive Summary: This US Patent is a divisional of earlier patents which claims a method of treating a subject suffering from a neoplastic condition or toxicity associated with an alteration in sphingolipid metabolism comprising administering to the subject an effective amount of a fumonisin analog. Structures and dosages are provided for various human diseases.
Technical Abstract: This patent was a divisional of U.S. Ser. No. 08/627,499 filed on Apr. 4, 1996, now U.S. Pat. No. 6,127,578, which was a divisional of U.S. Ser. No. 08/042,147, filed on Apr. 2, 1993, now U.S. Pat. No. 5,518,879 which is a divisional of U.S. Ser. No. 07/740,426, filed on Aug. 5, 1991, now U.S. Pat. No. 5,232,837. The current Patent 6,720,184 provides a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a fumonisin, or an analog thereof. The invention also provides a method of detecting the consumption of a fumonisin or a fumonisin analog in a subject comprising (A) detecting, in a sample from the subject, the state of the metabolic pathway of sphingolipids and (B) comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the consumption of a fumonisin or a fumonisin analog. Also provided is a method of detecting the presence of a fumonisin or fumonisin analog contamination in a sample from a food or feed comprising detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction indicating the presence of a fumonisin or fumonisin analog contamination. Furthermore, novel fumonisin analogs and compositions comprising fumonisins and fumonisin analogs are provided.